Tiadenol API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Tiadenol | CAS No: 6964-20-1 | GMP-certified suppliers
A medication that supports lipid profile modulation for potential management of dyslipidemias and related metabolic disorders in investigational applications.
Therapeutic categories
Product Snapshot
- Tiadenol is an oral small molecule formulated as a tablet
- It is primarily investigated for cardiovascular therapeutic applications
- The product is currently in experimental stages and not approved by major regulatory agencies
Clinical Overview
Tiadenol is currently categorized as an experimental agent, with limited publicly available data regarding its clinical indications and therapeutic applications. Although it is associated with lipid regulating activity, detailed pharmacodynamics and precise mechanisms of action have not been clearly established or disclosed in the literature. This classification suggests a focus on modulation of lipid profiles, possibly targeting dyslipidemias or related metabolic conditions; however, formal clinical validation remains absent.
Pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively reported. Without specific data on bioavailability, metabolic pathways, or elimination half-life, comprehensive ADME characterization is not available. This absence of detailed pharmacokinetic information presents challenges for clinical development and regulatory evaluation.
Safety and toxicity profiles for Tiadenol are likewise not well defined due to its experimental status. No substantial toxicological, adverse effect, or safety margin data have been published, necessitating careful consideration in investigational use and potential therapeutic exploration.
No notable brand names or marketed formulations of Tiadenol are currently recognized, reflecting its status outside widespread commercial or clinical utilization.
From an API sourcing and quality perspective, ensuring compliance with relevant pharmacopeial standards and purity specifications is critical due to the compound’s organosulfur chemical nature. Manufacturers and procurement teams should prioritize robust analytical characterization and stability data to support investigational or development-stage applications. Regulatory compliance and supply chain transparency remain essential given the compound’s experimental classification.
Identification & chemistry
| Generic name | Tiadenol |
|---|---|
| Molecule type | Small molecule |
| CAS | 6964-20-1 |
| UNII | 22251270CX |
| DrugBank ID | DB13348 |
Formulation & handling
- Tiadenol is a small molecule with low water solubility, suggesting the need for formulation strategies to enhance oral bioavailability.
- Given its classification as a dialkylthioether, it may possess moderate lipophilicity, impacting its absorption and distribution profiles.
- Formulation as a tablet indicates suitability for oral administration, with potential sensitivity to oxidation due to the organosulfur moiety requiring controlled storage conditions.
Regulatory status
Tiadenol is a type of Lipid-lowering agents
Lipid-lowering agents are a category of pharmaceutical active ingredients (APIs) that are widely used in the treatment of hyperlipidemia, a condition characterized by elevated levels of lipids (such as cholesterol and triglycerides) in the blood. These agents play a crucial role in managing lipid abnormalities and reducing the risk of cardiovascular diseases.
One of the most commonly prescribed lipid-lowering agents is statins. Statins work by inhibiting an enzyme called HMG-CoA reductase, which is responsible for the production of cholesterol in the liver. By blocking this enzyme, statins effectively lower cholesterol levels in the bloodstream.
Another class of lipid-lowering agents is fibric acid derivatives, which primarily target triglyceride levels. These agents activate a nuclear receptor known as PPAR-alpha, which regulates lipid metabolism. By activating PPAR-alpha, fibric acid derivatives enhance the breakdown of triglycerides and increase the elimination of fatty acids from the bloodstream.
Additionally, bile acid sequestrants are often used as lipid-lowering agents. These agents bind to bile acids in the intestine, preventing their reabsorption. As a result, the liver utilizes more cholesterol to produce new bile acids, leading to a decrease in circulating cholesterol levels.
Lipid-lowering agents are available in various formulations, including tablets, capsules, and suspensions, allowing for convenient administration. They are usually prescribed alongside lifestyle modifications, such as dietary changes and regular exercise, to optimize the management of hyperlipidemia.
It is important to note that the use of lipid-lowering agents should be under the supervision of a healthcare professional, as they may have potential side effects and interactions with other medications. Proper monitoring of lipid levels and regular follow-up visits are essential for ensuring the effectiveness and safety of these pharmaceutical agents.
